Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Pfizer (NYSE:PFE) and maintains a $45 price target.
June 20, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Pfizer and maintains a $45 price target.
The reiteration of an Overweight rating and a maintained price target of $45 by a reputable analyst can positively influence investor sentiment and potentially drive short-term price appreciation for Pfizer.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100